Avacopan (CCX168) is an experimental oral therapy being developed by ChemoCentryx to treat ANCA vasculitis. It is currently under review by both the U.S. Food and Drug Administration and European Medicines Agency. Applications for approval were based on data from a Phase 3 trial called ADVOCATE.
Benlysta (belimumab) is an approved therapy for lupus that is also being investigated to see if it can prevent flares or relapses in people with ANCA vasculitis. Benlysta is an antibody-based drug that blocks a chemical messenger in the blood known as BLyS or BAFF. As of 2019, the therapy was in Phase 3 testing for ANCA vasculitis.
Blisibimod is currently being developed for the treatment of IgA nephropathy, also known as Berger’s disease, but researchers believe it may also help treat ANCA vasculitis, an autoimmune disease characterized by the destruction and inflammation of small blood vessels. It has not yet been tested in people with ANCA vasculitis.
Orencia (abatacept) is approved for the treatment of rheumatoid arthritis. It also is used to treat psoriatic arthritis and juvenile idiopathic arthritis. The medicine is currently being investigated in Phase 3 trials for the treatment of patients with non-severe relapsing granulomatosis with polyangiitis (GPA), a type of ANCA vasculitis.